TXG Stock Overview
About the company
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.23 |
| 52 Week High | US$83.34 |
| 52 Week Low | US$23.81 |
| Beta | 1.73 |
| 1 Month Change | 4.62% |
| 3 Month Change | 46.70% |
| 1 Year Change | -25.90% |
| 3 Year Change | -16.27% |
| 5 Year Change | n/a |
| Change since IPO | -4.78% |
Recent News & Updates
Recent updates
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 0510x Genomics cut to Sell at Goldman Sachs on slower sales ramp
Aug 1810x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling
Jul 3010x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
Jul 1410x Genomics: Promising Growth From A Life Science Leading Single Cell Specialist
May 3110x Genomics, Inc. (NASDAQ:TXG): Is Breakeven Near?
Feb 18
Shareholder Returns
| TXG | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.4% | 1.1% | 1.3% |
| 1Y | -25.9% | -15.0% | -14.6% |
Return vs Industry: TXG underperformed the US Life Sciences industry which returned -15.6% over the past year.
Return vs Market: TXG underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| TXG volatility | |
|---|---|
| TXG Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: TXG's weekly volatility (9%) has been stable over the past year.
10x Genomics, Inc. Fundamentals Summary
| TXG fundamental statistics | |
|---|---|
| Market Cap | US$5.79b |
| Earnings (TTM) | -US$166.00m |
| Revenue (TTM) | US$516.41m |
11.2x
P/S Ratio-34.9x
P/E RatioIs TXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TXG income statement (TTM) | |
|---|---|
| Revenue | US$516.41m |
| Cost of Revenue | US$120.39m |
| Gross Profit | US$396.02m |
| Other Expenses | US$562.02m |
| Earnings | -US$166.00m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 76.69% |
| Net Profit Margin | -32.15% |
| Debt/Equity Ratio | 0% |
How did TXG perform over the long term?
See historical performance and comparison